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Abstract
Background: Several clinical studies have established the efficacy, safety, and tolerability of long-acting risperidone
administered once every 2 weeks in patients with schizophrenia or schizoaffective disorder. This report evaluates
preliminary efficacy, safety, tolerability, and pharmacokinetic data for a novel (once-monthly) administration of long-acting
injectable risperidone 50 mg in patients with schizophrenia or schizoaffective disorder.
Methods: Clinically stable patients participated in a 1-year, open-label, single-arm, multicenter pilot study. During the 4-
week lead-in phase, patients received long-acting risperidone 50 mg injections every 2 weeks, with 2 weeks of oral
risperidone supplementation. Injections of long-acting risperidone 50 mg every 4 weeks followed for up to 48 weeks,
without oral supplementation. The primary endpoint was relapse; other assessments included PANSS, CGI-S, adverse
event reports, and determination of risperidone and 9-hydroxyrisperidone plasma concentrations.
Results: Twelve patients in the intent-to-treat population (n = 67) met relapse criteria (17.9%). Relapse risk at 1 year was
estimated as 22.4%. Non-statistically significant improvements in symptoms (PANSS) and clinical status (CGI-S) at endpoint
were observed. The most common adverse events included schizophrenia aggravated not otherwise specified (19.5%),
anxiety (16.1%), insomnia (16.1%), and headache (11.5%). There were no unexpected safety and tolerability findings. Mean
plasma concentrations for risperidone and 9-hydroxyrisperidone were generally stable during the study.
Conclusion: Once-monthly dosing of long-acting risperidone was well tolerated, associated with a relatively low relapse
rate (similar to that reported with other antipsychotics), and maintained the clinically stable baseline status of most patients.
Although the results suggest that some symptomatically stable patients with schizophrenia or schizoaffective disorder might
be safely managed with long-acting risperidone 50 mg once monthly, these findings alone do not identify which patients will
have a sufficient therapeutic benefit nor do they quantify comparative effects of standard and altered dosing. Study
limitations (the open-label pilot study design, small sample size, and lack of a concurrent biweekly treatment arm) prevent
broad interpretations and extrapolations of results. Controlled studies would be required to support a recommendation
for alternative dosing regimens.
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Background
Schizophrenia is a chronic, debilitating disease that is
often characterized by frequent relapses associated with
exacerbation of psychosis and the need for psychiatric
rehospitalization [1]. To prevent relapse, compliance with
maintenance antipsychotic medication is critical.
Recently, the first long-acting injectable atypical antipsy-
chotic, long-acting risperidone, has become available and
is approved for administration every 2 weeks in patients
with schizophrenia. In contrast to conventional depots,
which are esterified prodrugs delivered in an oil-based
solvent, long-acting risperidone is an aqueous-based sus-
pension of microspheres of polylactide coglycolide, a bio-
degradable carbohydrate copolymer in which risperidone
is encapsulated. The release of risperidone from these
microspheres starts 3 weeks after the injection, with most
of the release occurring during weeks 4 through 6. Steady-
state plasma concentrations are reached after 4 injections
and are maintained for 4 to 6 weeks after the last injection.
Mean steady-state peak concentrations and peak-trough
fluctuations are reduced with long-acting risperidone
biweekly dosing compared with daily oral risperidone
dosing [2], potentially enabling further clinical improve-
ments with long-acting risperidone related to more pre-
dictable and stable drug plasma levels [2,3].
Several clinical studies have established the efficacy,
safety, and tolerability of long-acting risperidone admin-
istered once every 2 weeks in patients with schizophrenia
or schizoaffective disorder. Significant improvements in
the Positive and Negative Syndrome Scale (PANSS) total
score were observed relative to placebo in a 12-week, dou-
ble-blind, placebo-controlled trial in symptomatic
patients, and at endpoint relative to baseline in two 1-year
studies in patients with stable symptoms at study entry [4-
7]. The effect of long-acting risperidone on relapse has
also been studied in a 1-year, double-blind trial compar-
ing long-acting risperidone 25 mg and 50 mg every 2
weeks; relapse and rehospitalization rates were low, at
22% and 10%, respectively, in the 25-mg group; and 15%
and 6%, respectively, in the 50-mg group [7]. Long-term
treatment has demonstrated good tolerability, with few
discontinuations due to adverse events, minimal injec-
tion-site reactions, and significant improvements in
movement disorder ratings [4,6].
Efficacy and safety results from these studies suggest that
dosing of 25 mg up to 50 mg, administered every 2 weeks,
provides the optimum risk-to-benefit ratio for long-acting
risperidone; however, different approaches for mainte-
nance therapy with long-acting risperidone should be
explored. To date, examination of long-acting risperidone
using a longer injection interval has not been conducted,
although there has been clinical interest in extended-
interval dosing regimens. Single-dose pharmacokinetic
modeling with long-acting risperidone 50 mg once
monthly predicted average plasma concentrations similar
to that of 25 mg every 2 weeks, but with higher peak-to-
trough fluctuations and lower troughs (Janssen, L.P., data
on file), consistent with a previous report [8]. However,
because the relationship between medication blood levels
and clinical outcomes is not well characterized, a clinical
study is needed to assess the utility of such an approach.
The objective of this prospective pilot study is to examine
the efficacy, safety, tolerability, and pharmacokinetics of
maintenance treatment with long-acting risperidone 50
mg once monthly in stable patients with schizophrenia or
schizoaffective disorder.
Materials and methods
This prospective, open-label, 1-year, single-arm, multi-
center pilot study was performed between May 2002 and
December 2003, and included 12 sites in the United
States and Canada. The trial was conducted in accordance
with current Good Clinical Practice guidelines and the
Declaration of Helsinki and its subsequent revisions.
Independent ethics committees or institutional review
boards (IRBs) reviewed and approved the final protocol
and any amendments to the study.
Patients
Patients were aged 18 to 65 years with a diagnosis of schiz-
ophrenia or schizoaffective disorder according to DSM-IV
criteria [9]. Patients were judged to be symptomatically
and medically stable, with no other clinically significant
medical conditions. All patients received oral risperidone
monotherapy at a stable dose (2–6 mg/d) for 8 weeks
prior to baseline. Patients were excluded if they had signif-
icant symptom exacerbation (requiring hospitalization or
acute crisis intervention) in the 8 weeks prior to baseline;
were judged by the investigator to be at imminent risk of
injury to self, to others, or to property; had a history of
substance abuse within the past 6 months or a positive
substance test at screening; had impaired hepatic or renal
function; were pregnant or breastfeeding; or had received
treatment with an oral antipsychotic other than risperi-
done in the past 8 weeks, depot antipsychotics in the past
6 months, long-acting risperidone in a previous clinical
trial, another investigational agent within 30 days, or elec-
troconvulsive therapy within 12 months of baseline. Each
patient (or a relative, guardian, or legal representative)
provided written informed consent before participating in
the study.
Trial medication
Clinically stable patients receiving oral risperidone for at
least 8 weeks (2–6 mg/d) and meeting inclusion criteria
were eligible to enter the 52-week treatment phase, which
consisted of a 4-week lead-in phase and a 48-week
monthly injection and evaluation phase. During the lead-Annals of General Psychiatry 2007, 6:3 http://www.annals-general-psychiatry.com/content/6/1/3
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in phase, patients received injections of long-acting risp-
eridone 50 mg every 2 weeks, with 2 weeks of oral risperi-
done supplementation (2–6 mg/d) after the first long-
acting risperidone injection. During the monthly injec-
tion and evaluation phase, patients received long-acting
risperidone 50 mg every 4 weeks; oral risperidone supple-
mentation was not permitted. Long-acting risperidone
was administered by intramuscular gluteal injection.
Patients meeting relapse criteria had the option of receiv-
ing 75 mg once monthly, with oral risperidone supple-
mentation during the first 3 weeks after the first 75-mg
injection.
Patients were allowed to continue any antidepressants,
anxiolytics, or mood stabilizers if they had been receiving
stable doses for at least 8 weeks before baseline. Other
than oral risperidone treatment as described above, no
other antipsychotics were allowed. Zolpidem or zaleplon
were allowed for insomnia, lorazepam was permitted for
agitation or severe restlessness, and benztropine mesylate
was permitted for extrapyramidal symptoms.
Assessments
The primary efficacy parameter was time to relapse in the
intent-to-treat (ITT) population. The relapse incidences at
each follow-up time were estimated by Kaplan-Meier sur-
vival analysis. Relapse criteria were similar to those
reported previously [1] and were defined by any one of
the following: psychiatric hospitalization due to worsen-
ing symptomatology; a significant increase in the level of
psychiatric care required (eg, significant crisis intervention
needed to avert hospitalization, clinically notable
increases in the frequency or intensity of patient contact
required to maintain outpatient status), and a 25%
increase from baseline in the PANSS total score, occurring
within 2 weeks of one another; substantial clinical deteri-
oration, as indicated by a score of 6 ("much worse") or 7
("very much worse") on the Clinical Global Impressions
of Change (CGI-C) scale; or deliberate self-injury, suicidal
or homicidal ideation that is clinically significant as deter-
mined by the investigator, or violent behavior resulting in
clinically significant injury to another person or in prop-
erty damage. Efficacy parameters included the PANSS
total [10] and PANSS factor scores [11] and the Clinical
Global Impressions of Severity (CGI-S) scale [12], which
were assessed at baseline, weeks 2 and 4, and every 4
weeks thereafter.
Safety was assessed via regular monitoring of treatment-
emergent adverse events, laboratory tests, and vital signs.
The presence and severity of movement disorders were
evaluated by the Extrapyramidal Symptom Rating Scale
(ESRS)[13] and the Abnormal Involuntary Movement
Scale (AIMS) [12]. Treatment-emergent adverse events
and vital signs were monitored at each study visit; labora-
tory tests were performed at screening, baseline, and end-
point; the ESRS was performed at baseline and weeks 4, 8,
12, 16, 28, 40, and 52 (endpoint); and the AIMS was per-
formed at baseline and endpoint.
All patients were encouraged to return for their long-act-
ing risperidone injection within ± 3 days of their regularly
scheduled visit. Partial compliance/noncompliance with
injections was defined as receiving more than 25% of
injections outside this 3-day window for any of the study
time points.
Venous blood samples were taken for drug level measure-
ments; 5-mL trough samples were drawn from all patients
immediately before each injection at weeks 0, 2, and 4,
and every 4 weeks thereafter, including endpoint. More
intensive sampling occurred in a subset of patients (n =
18), from whom blood was drawn every 4 days between
weeks 24 and 28. Plasma concentrations of risperidone
and its active metabolite, 9-hydroxyrisperidone, were
determined by a validated liquid chromatography tandem
mass spectrometry (LC-MS/MS) method [14]. The follow-
ing pharmacokinetic parameters of the sum of risperidone
plus 9-hydroxy-risperidone were determined during the
period of intensive sampling in the subset of 18 patients:
apparent minimum plasma concentration at steady state
(Cmin,ss); apparent maximum plasma concentration at
steady state (Cmax,ss); time to reach the maximum plasma
concentration at steady state (tmax,ss); area under the
plasma concentration-time curve during a 4-week dosing
interval (τ) at steady state (AUCτ); average plasma con-
centration at steady state, calculated as AUCτ divided by
the dosing interval (τ) (Cavg,ss); fluctuation index (Fl), ie,
percentage fluctuation, calculated as 100* [(Cmax-Cmin)/
Cavg,ss]; and peak-to-trough ratios (Cmax/Cmin).
Data analysis
The sample size was not based on any statistical calcula-
tions for power, as this was an exploratory study. How-
ever, a sample size of 80 subjects entering the study was
deemed sufficient to allow for a preliminary exploration
of safety, tolerability, pharmacokinetics, and efficacy in
the context of an open-label, single-arm investigation,
with consideration of stratification factors described
below. Efficacy analyses were performed on the ITT popu-
lation, prospectively defined as patients who received at
least 1 injection of long-acting risperidone and who had
at least 1 efficacy evaluation during the monthly injection
and evaluation period of treatment (after week 4 of the
study). Safety evaluations were performed for all patients
who received at least 1 injection of long-acting risperi-
done. There were no adjustments made for multiplicity.
Time to relapse was determined using Kaplan-Meier
methodology. Ninety-five percent confidence intervals ofAnnals of General Psychiatry 2007, 6:3 http://www.annals-general-psychiatry.com/content/6/1/3
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the Kaplan-Meier estimates of the probability of relapse
were obtained using Greenwood's formula [15] for the
standard errors at 3 months, 6 months, and 1 year. For the
analysis of relapse, subjects were prospectively stratified
on the basis of the time since last hospitalization into 2
groups: between 2 and 6 months (56–167 days, inclu-
sive); and more than 6 months (168 days or longer), from
the first dose of long-acting risperidone. A post hoc anal-
ysis assessed relapse in patients with at least 1 efficacy
evaluation after week 8 in order to examine the effect of
the once-monthly administration only.
For other efficacy variables, changes from baseline and
observed values were summarized descriptively, including
95% confidence intervals at each time of evaluation and
at endpoint. A paired t  test for the difference between
baseline and endpoint was used for secondary parameters.
The pharmacokinetic analysis of risperidone plus 9-
hydroxyrisperidone was based on data from 771 of 957
samples collected from 87 patients. Excluded samples
included those taken outside the ranges for inclusion and
unscheduled samples (n = 75), samples taken while the
subject was taking oral risperidone cotherapy (n = 45),
and samples taken after injection with 75-mg long-acting
risperidone (n = 66). Descriptive statistics were calculated
at each scheduled sampling time and for steady-state
pharmacokinetic parameters during the intensive sam-
pling time between week 24 and week 28. Plasma concen-
trations below the limit of quantification (ie, <0.1 ng/mL
for risperidone and 9-hydroxyrisperidone for most sam-
ples, <0.2 ng/mL for 2 samples) were set to zero. Plots of
mean (± SD) plasma concentrations versus scheduled
time points are presented for the sum of risperidone plus
9-hydroxyrisperidone.
Results
A total of 87 patients participated in this pilot study and
were included in the safety analyses. The mean (± SD) ris-
peridone oral dose was 3.9 (1.2) mg/d during the 2-week
screening period and 4.0 (1.5) mg/d during the long-act-
ing risperidone 4-week lead-in period. The mean patient
age (± SD) was 39.8 ± 10.3 years, 58 (66.7%) were male,
and the majority (78.2%) had a diagnosis of schizophre-
nia. Thirty-five (40.2%) were Caucasian, 31 (35.6%) were
Black, 19 (21.8%) were Hispanic, and 2 (2.3%) were
Other. Reasons for study discontinuation, including
relapse, are listed in Figure 1. Overall, 75.9% of the
patients were compliant, as defined in the Methods sec-
tion.
Efficacy
At the end of the study, 12 patients (17.9%) in the ITT
population (n = 67) had relapsed. Six patients required
psychiatric hospitalization and 6 patients experienced
substantial clinical deterioration. The Kaplan-Meier esti-
mate of the risk of relapse in the ITT population at 1 year
was 22.4% (95% confidence interval, 10.9%–33.9%)
(Figure 2). Of the 22 patients in the ITT population with
a recent hospitalization prior to study entry, 4 (18.2%)
met criteria for relapse during the trial. Of the 45 patients
with a hospitalization more than 167 days from the first
dose of long-acting risperidone, 8 (17.8%) met criteria for
relapse. The time to relapse curves were similar for these 2
groups. Median time to relapse could not be calculated
since fewer than 50% of subjects relapsed over the 52
weeks of the trial.
A post hoc analysis was performed to assess relapse in
patients with at least 1 efficacy evaluation after week 8 to
examine the effect of once-monthly dosing only. The
number who relapsed (n = 12) and the Kaplan-Meier esti-
mate of the risk of relapse were the same as in the ITT pop-
ulation because, even though there were 3 fewer patients
in this post hoc population (n = 64), none of those 3
patients met relapse criteria (1 withdrew consent and 2
discontinued owing to adverse events).
The mean PANSS total score improved over the course of
the study in this population of symptomatically stable
patients; the improvement was significant at all time
points, including week 52 (completers), but not at end-
point (LOCF analysis; Table 1). Analysis of PANSS factor
scores indicated that all five (positive, negative, anxiety/
depression, uncontrolled hostility/excitement, and disor-
ganized thought factor scores) were significantly
improved (P < .01) at week 52, but not at endpoint (Table
1).
Mean CGI-S scores improved over the course of the study.
The improvement was significant at week 52 (completers)
compared with baseline (P = .0002), but not at endpoint
(LOCF analysis). The number (%) of patients with a cate-
gorical CGI-S rating of not ill to mildly ill increased from
34 (50.8%) at baseline to 42 (62.7%) at endpoint (Table
2).
Eight subjects in the ITT population relapsed while receiv-
ing 50 mg once monthly, and then continued in the study
with the 75 mg once monthly dose. Efficacy data are avail-
able for 6 of these subjects. Mean total PANSS scores
improved from 88.4 ± 21.8 at baseline (baseline was
defined at the start of the 75 mg dosing period) to 65.8 ±
10.7 at endpoint. The mean CGI-S score also improved,
from 5.0 ± 0.6 at baseline to 4.2 ± 1.2 at endpoint.
Although positive, these results should be interpreted
with caution due to the small number of subjects for
whom data were available.Annals of General Psychiatry 2007, 6:3 http://www.annals-general-psychiatry.com/content/6/1/3
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Safety and tolerability
A total of 67 patients (77.0%) experienced at least 1
adverse event during the study, and 9 patients (10.3%)
discontinued the study owing to adverse events. The
majority of adverse events reported were mild or moder-
ate in severity. The most common adverse events
(reported by more than 10% of subjects) included schizo-
phrenia aggravated not otherwise specified (NOS;
19.5%), anxiety (16.1%), insomnia (16.1%), and head-
ache (11.5%). The incidence of movement disorder
adverse events was low: tremor (4.6%), dyskinesia
(3.4%), akathisia (2.3%), hypertonia (2.3%), and dysto-
nia (1.1%). Only 2 patients (2.3%) reported pain at the
injection site.
There were 25 reports of serious adverse events (SAEs),
representing 18 patients, during the course of the trial. No
deaths occurred in this study. Of the 13 SAEs rated as
severe, 1 (schizophrenia NOS aggravated) was categorized
as possibly and 1 (weight decreased) as very likely related
to the trial medication.
ESRS subscale scores of particular interest include the
overall movement disorder subjective score, the physi-
cian's examination of parkinsonism, and the physician's
examination of dyskinesia. Mean scores were unchanged
or improved at endpoint in each of these subscales, with
mean (± SD) scores (baseline, endpoint) as follows:
movement disorder subjective score: 1.7 (2.3), 1.3 (2.1);
physician's examination of parkinsonism: 2.3 (4.7), 0.9
(2.0); and physician's examination of dyskinesia: 1.0
(2.1), 0.9 (2.2). Improvement in the parkinsonism sub-
scale was significant at week 52 (P < .05) and endpoint (P
< .01). Mean scores on the dystonia and akathisia sub-
scales were low (<1) both at baseline and endpoint. The
mean (± SD) total AIMS score at baseline was low, 1.5
(2.8), and improved during the study, with a mean (± SD)
change from baseline at week 52 of -0.9 (2.9) and at end-
Study disposition Figure 1
Study disposition. *Eight patients in the safety population were not part of the prospectively defined ITT population (n = 67) 
for which the primary endpoint, relapse incidence, was calculated. Twenty patients in the safety population, versus 12 patients 
in the ITT population, relapsed.
Patients screened 
(n = 105)
Excluded (n = 18)
   Did not meet inclusion criteria (n =13)
   Other reasons (n = 5)
Patients enrolled 
(n = 87)
Safety population: Patients who received at least 1 
dose of study medication
(n = 87)
Intention-to-treat (ITT) population: Patients 
who received at least 1 dose of study 
medication and ≥1 efficacy evaluation after 
week 4 during the monthly phase of the 
study 
(n = 67)
Discontinued the study (n = 54)
• Relapse (n = 20)*
￿ Withdrawal of consent (n = 11)
￿ Adverse events (n = 9)
￿ Lost to follow up (n = 8)
￿ Other (n = 4)
￿ Protocol violation (n = 2)
Completed the study (n = 33)Annals of General Psychiatry 2007, 6:3 http://www.annals-general-psychiatry.com/content/6/1/3
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point of -0.2 (3.7); the change from baseline was not sig-
nificant at either time point (P = .090 at week 52; P = .662
at endpoint).
There were no clinically meaningful changes on mean lab-
oratory values, mean vital signs, or electrocardiogram
(ECG) parameters. The mean (± SD) random blood glu-
cose level was 109.8 (35.6) mg/dL at baseline and
remained stable throughout the study, with a mean (±
SD) change of 5.0 (34.5) mg/dL from baseline at week 52.
The mean (± SD) prolactin level at baseline was 43.1
(41.0) ng/mL and remained stable during the study; there
was a mean decrease of 1.1 (37.64) ng/mL from baseline
at week 52. The mean (± SD) body weight at baseline was
92.8 (24.5) kg, with a mean change of -0.3 (5.5) kg from
baseline to endpoint.
Pharmacokinetic analysis
The pharmacokinetic analysis of risperidone plus 9-
hydroxyrisperidone was based on data from 771 samples
from 87 patients. Mean plasma concentrations for risperi-
done plus 9-hydroxyrisperidone were generally stable
throughout the study (Figure 3). During steady state,
obtained with samples from 18 patients, the average
plasma concentration of risperidone plus 9-hydroxyrisp-
eridone was 17.5 (6.1) ng/mL, and the fluctuation index
was 199% (55.8) (Table 3).
Discussion
Short- and long-term studies of long-acting risperidone
have suggested an optimal population benefit/risk ratio at
doses of 25 mg up to 50 mg administered every 2 weeks,
the dosing interval for which this product has been
approved [4-7]; however, there is clinical interest in the
possibility of a longer injection schedule, and models
derived from single-dose pharmacokinetic data at the 50-
mg dose suggested that 50 mg every 4 weeks would result
in average plasma concentrations similar to those with 25
mg given every 2 weeks, albeit with higher peak-to-trough
fluctuations and lower trough levels (Janssen Pharmaceu-
tica, Inc., data on file). To date, there are no published
reports supporting alternative dosing intervals with long-
acting injectable risperidone, and important clinical ques-
tions on the associated tolerability, safety, and efficacy
associated with a longer injection interval remain unan-
swered. We explored these issues as well as the pharma-
cokinetics of once-monthly administration of long-acting
risperidone 50 mg in a small pilot study of stable patients
with schizophrenia or schizoaffective disorder. Since this
is the first clinical study assessing a monthly dosing regi-
men, a pilot approach was chosen to minimize potential
risk to a larger number of patients.
The relapse rate was relatively low (17.9%) in this 1-year
study of patients clinically stable at study entry receiving
Table 1: Positive and Negative Syndrome Scale (PANSS) Scores at Baseline, Week 52, and Endpoint (Intention-to-Treat Population)
PANSS, mean ± SD Baseline (N = 67) Week 52 (n = 31) LOCF Endpoint (N = 67)
Total 65.4 ± 13.5 57.5 ± 12.7 61.7 ± 17.9
P < .0001 P = .087
Positive symptoms 18.1 ± 5.3 15.6 ± 4.5 17.3 ± 6.2
P < .0001 P = .233
Negative symptoms 17.4 ± 5.4 16.0 ± 4.4 16.1 ± 5.4
P = .007 P = .071
Anxiety/depression 9.1 ± 3.0 7.3 ± 2.7 8.5 ± 3.7
P = .002 P = .133
Disorganized thought 14.4 ± 4.1 13.4 ± 3.8 13.9 ± 4.2
P = .001 P = .337
Uncontrolled hostility/excitement 6.3 ± 2.4 5.3 ± 1.7 5.9 ± 2.4
P = .001 P = .278
P values represent significance of change from baseline, paired t test. LOCF indicates last observation carried forward.
Kaplan-Meier survival curve for relapse, intention-to-treat  (ITT) population Figure 2
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once-monthly long-acting risperidone 50 mg; the Kaplan-
Meier estimate of the risk of relapse at 1 year was 22.4%.
No meaningful difference was observed in the rate of
relapse between subjects with a recent hospitalization and
those with a longer time since last hospitalization. While
it is difficult to make comparisons across studies for many
reasons, including differences in relapse criteria, this
relapse incidence is similar to those found in US-based
clinical trials examining long-acting injectable antipsy-
chotics [16-20]. A head-to-head comparison of risperi-
done and haloperidol found 1-year relapse rates were
25.4% for patients receiving risperidone 2–8 mg/d vs
39.9% for haloperidol 5–20 mg/d [1]. One-year rates of
relapse for ziprasidone were 43%, 35% and 36% for doses
of 40, 80, and 160 mg/d, respectively [20], whereas treat-
ment with fluphenazine decanoate 12.5–100 mg/3 weeks
was associated with a 1-year relapse rate of 28% [19].
Other relapse data for long-acting risperidone are availa-
ble from a randomized, double-blind, 52-week study of 2
doses of long-acting risperidone (25 or 50 mg) adminis-
tered every 2 weeks. One-year relapse incidence was
21.6% and 14.9% for patients receiving the 25 mg and 50
mg doses, respectively [7].
Although patients were symptomatically stable at base-
line, additional efficacy analyses showed that significant
improvements were noted on the PANSS and the CGI-S
scores throughout the study, except at endpoint, demon-
strating maintenance or improvement of symptom con-
trol. In this study, the mean change from baseline in the
PANSS total score at endpoint was -3.7 (17.7); P = .087.
Significant improvements in PANSS total scores were
observed at endpoint in 2 other long-term studies of long-
acting risperidone [4,7]. In a 1-year, open-label study that
included 561 patients, the mean (± SE) change in PANSS
total score at endpoint was -6.1 (0.7), P < 0.01 vs baseline
[4]. In a randomized, double-blind, 52-week study that
included 323 patients, the mean (± SD) change in PANSS
total score was -4.9 (16.8), P ≤ .001 vs baseline [7]. Base-
line total PANSS scores in this study and the other 1-year
studies [4,7] were similar. The smaller numbers of
patients in the current study may explain the differences
in significance in PANSS total scores at endpoint. As
relapse prevention and symptom control are key goals in
the treatment of chronic schizophrenia, these results sug-
gest that some symptomatically stable patients with schiz-
ophrenia or schizoaffective disorder might be safely
managed with long-acting risperidone 50 mg once
monthly; however, these data do not allow us to distin-
guish those patients for whom this dosing regimen may
be sufficient versus those for whom it may be suboptimal,
nor does this pilot design permit firm conclusions con-
Table 3: Steady-State Pharmacokinetic Parameters of Risperidone Plus 9-hydroxyrisperidone with 50 mg Once-Monthly or 25 mg 
Biweekly
50 mg Once Monthly* 25 mg Biweekly [2]
Parameter n Mean ± SD n Mean ± SD
Cmin,ss, ng/mL 18 6.21 ± 3.1 21 11.3 ± 4.5
Cmax,ss, ng/mL 18 40.4 ± 15.3 21 22.7 ± 9.2
tmax,ss, h 18 240.2 ± 217.2 21 NA
AUCτ, ng·h/mL 17 12,027 ± 4241 21 5303
Cavg,ss, ng/mL 17 17.5 ± 6.1 21 15.8
FI, % 17 199 ± 55.8 21 69 ± 44
Cmax/Cmin r a t i o 1 87 . 4  ±  2 . 82 12 . 4  ±  1 . 8
NA indicates not available.
*Samples acquired between weeks 24 and 28.
AUCτ: the dosing interval (τ) is 4 weeks for the present study and 2 weeks for Eerdekens M, et al.
Table 2: Clinical Global Impressions of Severity (CGI-S) Categorical Ratings at Baseline and Endpoint (Intention-to-Treat Population)
CGI-S Rating Baseline (N = 67) n (%) Endpoint (n = 67) n (%)
Normal 0 0
Borderline mentally ill 2 (3.0) 11 (16.4)
Mildly ill 32 (47.8) 31 (46.3)
Moderately ill 25 (37.3) 13 (19.4)
Markedly ill 8 (11.9) 11 (16.4)
Severely ill 0 1 (1.5)Annals of General Psychiatry 2007, 6:3 http://www.annals-general-psychiatry.com/content/6/1/3
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cerning comparative efficacy or tolerability of the alterna-
tive dosing regimen.
In addition to a relatively low relapse rate and mainte-
nance of effect in most patients, other results of this pilot
study suggested that long-acting risperidone 50 mg once
monthly was well tolerated, with a safety profile similar to
that reported for long-acting risperidone administered on
a biweekly schedule [4,6,7]. Movement disorder ratings
were all low at baseline in this population and were
unchanged or improved during the study. There were no
clinically meaningful changes in mean laboratory values,
vital signs, or ECG parameters. The mean body weight
decreased modestly over the course of this study. In con-
trast, small mean body weight increases were noted in two
other 1-year studies of long-acting risperidone in which
risperidone was administered biweekly [4,7]. Overall, this
pilot data suggests that the monthly dosing regimen may
Mean (± SD) plasma concentrations of risperidone plus 9-hydroxyrisperidone by study week Figure 3
Mean (± SD) plasma concentrations of risperidone plus 9-hydroxyrisperidone by study week. Pharmacokinetic (PK) analyses 
are based on 771 samples from 87 patients. Intensive pharmacokinetic data are based on 7 samples planned between weeks 24 
and 28 (1 every 4 days) from 18 patients.
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not have greater liability regarding safety or tolerability
compared with biweekly dosing.
Single-dose pharmacokinetic modeling with long-acting
risperidone 50 mg once monthly predicted average
plasma concentrations similar to those seen with 25 mg
given every 2 weeks, but with higher peak-to-trough fluc-
tuations and lower troughs, resulting in intermittent peri-
ods of low exposure (Janssen, L.P., data on file).
Consistent with those data, the pharmacokinetic results
showed more variability with once-monthly compared
with biweekly dosing. Indeed, Cmin values associated with
the 50-mg monthly injections were approximately half of
the steady-state values measured in another study of long-
acting risperidone injection 25 mg administered biweekly
[2]. Further, the percentage fluctuation and the Cmax-to-
Cmin  ratios were approximately 3 times higher after
monthly injections than after biweekly injections;[2]
however, the average exposure to risperidone plus 9-
hydroxyrisperidone was comparable between once-
monthly dosing and historical data from biweekly dosing.
While previous reports have suggested that greater plasma
level fluctuations may be associated with poorer tolerabil-
ity [2,3], this was not supported in the overall results from
this pilot study.
Conclusion
The intent of this pilot study was to begin addressing a
critical clinical question regarding alternative dosing fre-
quency with long-acting risperidone, particularly once-
monthly administration. Once-monthly dosing of long-
acting risperidone appeared to maintain the baseline
symptomatic status of stable patients with schizophrenia
or schizoaffective disorder, with no unexpected safety and
tolerability findings. While the results are encouraging,
interpretations are limited by several factors, including the
open-label pilot study design, small sample size, and lack
of a concurrent biweekly treatment arm. Further, addi-
tional information on illness course in patients prior to
risperidone therapy would also have been helpful for
interpreting the study findings.
Despite the limitations of the trial, the findings support a
possible role for risperidone long-acting 50 mg once
monthly in certain stable patients with schizophrenia or
schizoaffective disorder. A controlled trial evaluating both
a biweekly and monthly administration regimen would
be necessary, however, to further explore the clinical
impact of once-monthly relative to biweekly dosing.
Results from this trial will help provide direction for
future controlled studies to validate alternative dosing reg-
imens with long-acting risperidone.
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